Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;49(4):671-688.
doi: 10.1016/j.gtc.2020.08.003. Epub 2020 Sep 23.

Assessing Severity of Disease in Patients with Ulcerative Colitis

Baldeep Singh Pabla  1 , David Allen Schwartz  2
Affiliations
Review

Assessing Severity of Disease in Patients with Ulcerative Colitis

Baldeep Singh Pabla et al. Gastroenterol Clin North Am. 2020 Dec.

Abstract

Ulcerative colitis (UC) is a chronic disease that can present at various stages of disease activity and severity. Traditionally, severity scoring has focused on disease activity during a single moment with various tools, including patient-reported symptoms, as well as clinical, laboratory-based, endoscopic, histologic, and imaging variables. Optimal delivery of care depends on the accurate assessment of disease severity, which must take longitudinal variables into account. This article reviews the history of severity scoring in UC and provides a concise, clinically oriented approach to assessing disease severity.

Keywords: CRP; Clostridium difficile; Mayo score; PRO; Truelove and Witts; UCEIS.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr B.S. Pabla has no relevant financial disclosures. Dr D.A. Schwartz has the following financial disclosures: Abbvie, consultant; UCB, consultant, grant support; Janssen, consultant; Takeda, consultant; Gilead, consultant; Pfizer, consultant; Genetech, consultant.

References

    1. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041–1048. - PMC - PubMed
    1. Peyrin-Biroulet L., Panés J., Sandborn W.J., et al. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016;14(3):348–354.e17. - PubMed
    1. D’Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–786. - PubMed
    1. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1(5375):89–92. - PMC - PubMed
    1. Powell-Tuck J., Bown R.L., Lennard-Jones J.E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13(7):833–837. - PubMed